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This case study examines selective Pittsburgh compound-B (PiB) binding to an 
intracerebral light-chain amyloidoma using a 90-minute dynamic [11C]PiB-PET scan 
and brain biopsy tissue. Parametric non-displaceable binding potential (BPND) images 
showed negligible specific binding in the amyloidoma, while relative tracer delivery 
(R1) was adequate. Histology of the tissue revealed strong colouring with congo-red, 
thioflavin-S, and X-34, indicating presence of amyloid. However, immunological 
staining with 6F/3D revealed absence of amyloid-β and histofluorescence of 6-CN-
PiB, a highly fluorescent derivative of PiB, was negligible. These results suggest that 



















The development of positron emission tomography (PET) amyloid ligands such as 
[11C]Pittsburgh compound-B (PiB) [1], have provided a non-invasive tool to assess 
amyloid-β (Aβ) pathology in vivo. PiB has been shown to bind strongly to fibrillary 
Aβ40-42 [2,3], and elevated binding of [11C]PiB is consistently observed in patients 
with sporadic Alzheimer’s disease (AD) [4], even in very early stages of the 
disease.[5] However, several studies reported undetectable levels of [11C]PiB PET 
retention in subjects with histologically detectable, albeit non abundant, Aβ pathology 
at time of autopsy or biopsy.[6-8] In addition, there are exceptional cases where 
[11C]PiB retention was low in patients clinically diagnosed with AD [9-11], even in 
the presence of heavy cortical Aβ deposition in post-mortem tissue.[10] Furthermore, 
in contrast to findings in APP duplication, Swedish APP mutation and presenilin-1/2 
mutation carriers who all show levels of [11C]PiB retention typical of late-onset AD 
[12, 13], patients with the “Arctic” APP mutation display very low [11C]PiB retention, 
while cerebrospinal fluid levels of Aβ1-42 indicate presence of amyloid pathology.[14] 
An explanation for this discrepancy is offered by histological examination in “Arctic” 
APP carriers which revealed that amyloid depositions in these patients are mainly 
characterized by non-fibrillary amyloid pathology, such as protofibrils and 
oligomers.[15.16] In vitro and animal studies have shown that, at nanomolar 
concentrations administered to the living human brain, [11C]PiB does not bind equally 
to all isoforms [2,17-19] and conformations [3,20] of amyloid equally. 
Here we present a case of a 52 year-old woman with an intracerebral light-
chain amyloidoma, a form of solitary localised, tumoral amyloidosis.[21-23] The 
diagnosis of intracerebral amyloidoma is made on the basis of histological 
examination of biopsy material, which is obtained through an invasive procedure. We 
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examined whether the atypical form of amyloid pathology found in intracerebral 
amyloidoma can also be visualized in vivo with [11C]PiB-PET imaging, by 
quantitatively assessing [11C]PiB binding in combination with histology from a brain 
biopsy performed during life. 
 
MATERIALS AND METHODS 
Case description 
The 52 year-old patient was referred to the hospital because of an epileptic seizure. Her 
past medical history was uneventful. However, in the period leading up to the epileptic 
seizure, a remarkable change in personality was observed with a lack of initiative. 
Magnetic resonance imaging (MRI) revealed an intracranial solid neoplasm within the 
white matter of the right frontal lobe with both high and low intensities on T1 (Figure 
1A) and FLAIR (Figure 1B). Administration of gadolinium showed a patchy enhancement 
of the lesion and spectroscopic examination revealed low N-acetyl aspartate and high 
choline levels, without lipids or lactate. All observations considered, the most probable 
diagnosis was an intracerebral amyloidoma.[21-23] Brain biopsy was performed to 
confirm this suspicion, which indeed revealed histological evidence for light-chain 
amyloidosis (not shown).[24] [11C]PiB and [18F]FDG-PET scans were performed two 
years after the diagnosis was made, and the remains of the brain biopsy were examined 
with additional histological stains. All procedures performed were in accordance with 
the ethical standards of the institutional research committee and with the 1964 Helsinki 
declaration and its later amendments. Informed consent was obtained from all 







A 90-minute dynamic [11C]PiB-PET scan protocol was performed using an ECAT 
EXACT HR+ scanner (CTI/Siemens, Knoxville, TN, USA). PET sinograms were 
corrected for dead time, tissue attenuation, decay, scatter, and randoms. Next, data 
was reconstructed using a standard filtered back projection algorithm and a Hanning 
filter with a cut‐off at 0.5 times the Nyquist frequency. A matrix size of 256x256x63 
was used, resulting in a voxel size of 1.2x1.2x2.4 mm and spatial resolution of 
approximately 7 mm full width at half‐maximum at the center of the field of view. An 
MR image was aligned to the PET image using a mutual‐information algorithm and 
PVE‐lab, a software program that uses a probability map [25], was used to project 
PET data onto the structural MRI. PET data were analyzed using receptor parametric 
mapping with fixed efflux rate constant (RPM2) [26], generating parametric non-
displaceable binding potential (BPnd) and R1 images using cerebellar gray matter as 
reference tissue. R1 represents the relative tracer delivery to the target tissue and 
provides an indication of flow. Furthermore, a standardized uptake value ratio (SUVr, 
60-90 minute) image was generated using cerebellar gray matter as reference. 
Detailed information on scanning protocol and data analysis procedures are described 
elsewhere.[26]  
We visually assessed the amyloidoma on [11C]PiB-R1, BPnd and SUVr images. 
Furthermore, [11C]PiB-R1, BPnd and SUVr values were also assessed quantitatively by 
manually delineating the amyloidoma on MRI and calculating these parameters within 
the amyloidoma using an volume-of-interest (VOI) delineation tool. This VOI tool is 
built in-house and is used to manually draw VOI on MRI or PET images. The tool 
provides with a binary image of VOI that can be superimposed onto the PET scan to 
extract the time activity curve i.e the average activity in the VOI over time.  
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R1, BPnd and SUVr values within the volume of the amyloidoma were 
compared with values in a contralateral VOI, which matched the size and anatomical 
location of the amyloidoma (Figure 2). Finally, for the [18F]FDG PET scan we 
generated a SUVr image for the interval between 45-60 minute using cerebellar gray 
matter as the reference region.[26]  
 
Histology 
The tissue of the amyloidoma acquired by brain biopsy during life was examined 
using staining for congo-red and thioflavin-S, and immunologic staining for amyloid-
β (using the monoclonal antibody 6F/3D [27]). Tissue from the amyloidoma was then 
additionally assessed using histofluorescence of 6-CN-PiB [28] (a highly fluorescent 
derivative of PiB), and X-34 [29] (a highly fluorescent derivative of congo red). As a 
reference, histofluorescence of 6-CN-PiB and X-34 was also assessed in frontal 





[18F]FDG revealed a large hypometabolic region in the right frontal lobe extending 
beyond the location of the amyloidoma (Figure 1C). [11C]PiB-PET showed low binding 
in cortical areas with relatively high uptake in the subcortical white matter (Figure 
1D,E), similar to patterns observed in most healthy controls.[1] At the location of the 
amyloidoma, within the white matter, [11C]PiB binding was low, as indicated by both 
BPND (Figure 1D) and SUVr (Figure 1E)  images. BPND within the volume of the 
amyloidoma (8.60 mL) was 0.24, whilst BPND within the volume of the contralateral 
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VOI (6.57 mL) was 0.46. Corresponding SUVr values for amyloidoma and 
contralateral VOI were 1.33 and 1.44, respectively. Furthermore, the R1 image showed 
that tracer delivery to the amyloidoma (Figure 1F), was only slightly lower than to the 
contralateral VOI (0.44 and 0.56, respectively).  
 
Histology 
The brain biopsy tissue was clearly positive with congo-red (Figure 3A) and thioflavin-
S staining (Figure 3B), indicating presence of amyloid. However, immunological 
staining with 6F/3D revealed that there was no amyloid-β present in the amyloidoma 
tissue (Figure 3C). Additional histological examinations revealed a prominent staining 
of amyloid with X-34, similar as in the AD “positive control” (Figure 3D,E), again 
indicating the presence of amyloid. However, 6-CN-PiB was at background levels 




Our results indicate that [11C]PiB does not bind cerebral amyloid pathology associated 
with a light-chain intracerebral amyloidoma. Quantitative analysis revealed that 
[11C]PiB binding was negligible, despite tracer being delivered to the tissue. 
Furthermore, histological examination of brain biopsy tissue revealed a convincing 
explanation for the lack of [11C]PiB binding, as the strong colouring with congo-red, 
thioflavin-S and X-34 were suggestive of presence of amyloid, but the lack of 6F/3D 
staining indicated that there was no fibrillary amyloid-β pathology present. 
Furthermore, in keeping with the [11C]PiB-PET findings we observed no 
histofluoresence of 6-CN-PiB in the amyloidoma tissue. These results highlight that 
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PiB selectively binds to fibrillar Aβ pathology [2,3], and does not detect the atypical 
amyloid pathology found in this case of intracerebral amyloidoma. 
To date, only one other study assessing accordance between in vivo amyloid 
imaging and histology in intracerebral amyloidoma has been published.[30] Contrary 
to our findings, PET imaging with [18F]Florbetapir (a different amyloid-β tracer) 
revealed slightly increased uptake in the region of the amyloidoma and histology 
showed weak staining for amyloid-β. One explanation for this discrepancy could be 
the heterogeneity between subjects (e.g. the absence or presence of fibrillary amyloid-
β in the amyloidoma) as previous literature has described cases of intracerebral 
amyloidoma with histological evidence for amyloid-β (see [23] for a review). More 
likely, however, are factors associated with the pharmacokinetics of the different 
tracers. [18F] amyloid imaging ligands tend to show higher nonspecific uptake in 
white matter [31], which may, due to the location of the amyloidoma (within the 
white matter), have convoluted interpretation of results. In addition, two studies 
[32,33] have reported PiB detection of systemic light-chain amyloidosis. One study 
assessed in vivo [11C]PiB-PET binding in the heart [32] and the other assessed in 
vitro [3H]PiB binding in the liver and spleen [33].  However, the affinity of [3H]PiB 
for systemic amyloid was 448 ± 185nM in these systemic tissues; compared to 3.84 ± 
0.04nM in AD brain [33].  Such low-affinity binding would not be expected to be 
detectable with in vivo brain PET. 
Strengths of the present study include the implementation of a dynamic PET 
scan, which enabled us to assess tracer delivery (R1) and [
11C]PiB binding in a 
quantitative manner.[26] Furthermore, the study is unique in combining dynamic 
[11C]PiB-PET with histological examination of biopsy material. Some limitations of 
the present study also need to be taken into account. Localized amyloidosis, 
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characteristic of the amyloidoma, rarely affects the brain.  Consequently, literature on 
this topic is sparse, with only around 30 cases having been described.[21-23, 30] This 
paucity of available literature, in combination with the heterogeneity in clinical and 
radiological presentations across cases, prevents us from making any conclusions 
about intracerebral amyloidoma in general.  
Taken together, our results highlight the selective binding of [11C]PiB to 
fibrillary Aβ and indicate that [11C]PiB does not bind to amyloid pathology associated 
with light-chain intracerebral amyloidoma.  
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Fig. 1 Axial T1, FLAIR, [18F]FDG-SUVr and [11C]PiB BPnd, SUVr and R1 PET 
images of the amyloidoma 
T1 (A) and FLAIR (B) images show the intracerebral amyloidoma in the right frontal 
lobe. FDG-PET (C) shows hypometabolism at the location of the amyloidoma. BPnd 
(D) and SUVr (E) images reveal lack of PiB-binding in the amyloidoma, while the R1 
(pseudo-flow; F) image indicates that tracer is being delivered to the amyloidoma.  
FDG – Fluodeoxyglocose, FLAIR – fluid-attenuated inversion recovery, MRI – 
magnetic resonance imaging, PiB – Pittsburgh compound B, BPnd – non-displaceable 


























Fig. 2 Amyloidoma and contra-lateral volume of interest  
In the left panel, the manual delineation of the amyloidoma is presented in red and the 
contra-lateral volume-of-interest is presented in blue. The right panel displays time-
activity curves of the amyloidoma and contra-lateral volume of interest. 


















Fig. 3 Histological staining, immunohistochemistry and histofluorescence in 
sections from the amyloidoma and additional histofluorescence in frontal cortex 
of an end-stage AD “positive control” 
Congo-red (A) and thioflavin-S (B) stainings indicated presence of amyloid but 6F/3D 
immunohistochemistry (C) revealed no indication for Aβ pathology. Additional, X-34 
histofluorescence in different sections of the biopsy material (D) again revealed 
presence of amyloid, similar as in the AD positive control (E). However, absence of 
histofluorescence with 6-CN-PiB in the amyloidoma (F), in contrast to the AD 
positive control (G), reveals lack of PiB binding.  




Figure 2. X-34 (A,B) and 6-CN-PiB (C,D) histofluorescence
in sections from the myloidoma (A,C) and in frontal cortex 
sections from a positive control case with Alzheimer’s 
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